The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.
Research output: Contribution to journal › Article
Colleges, School and Institutes
WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of
|Journal||British Journal of Clinical Pharmacology|
|Publication status||Published - 28 Sep 2011|